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del(17p), t(14;16) and t(14;20); intermediate by t(4;14), 1qgain,
complex karyotype, hypodiploidy or metaphase detected
del13, while standard risk MM is characterized by all other
aberrations including trisomies (especially of chromosomes 3,enetic studies play a central role in the study of multiple
yeloma (MM),  as they are a critical component in the risk-
ased classiﬁcation of the disease. Signiﬁcant effort has been
ade to identify and include genetic markers in the routine
linical care. The work by Kishimoto on interphase ﬂuores-
ence in situ hybridization (iFISH) of puriﬁed CD138 cells is an
xample of such effort.
iFISH in puriﬁed plasmatic cells is one of the most used
echniques in the clinical practice due to its straight forward
mplementation and simplicity of data analysis. iFISH is today
he standard tool to detect genetic abnormalities and for dis-
ase prognostication.
It is worth mentioning that other genomic–transcriptomic
echniques used in the risk-based classiﬁcation of MM
atients such as comparative genomic hybridization (aCGH),
ext generation sequencing (NGS) and gene expression proﬁl-
ng (GEP or RNAseq), also need to be performed in puriﬁed MM
ells to ensure accurate results. This fact makes Kishimoto’s
rticle of the utmost importance.DOI of original article: http://dx.doi.org/10.1016/j.bjhh.2016.01.005.
 See paper by Kishimoto et al. on pages 113–20.
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MM is a hematological malignancy characterized by an abnor-
mal  accumulation of clonal plasma cells (PC) in the bone
marrow (BM). Genetic alterations are observed from the early
stages of the disease and are key events in the establishment of
the clonal PC population. Genetic alterations have been used
as a basis to classify the disease and patients into different
prognostic groups and, more  importantly, may be used in the
near future as predictive markers of therapeutic response.
The Mayo Clinic1 proposed a simpliﬁed genetic based clas-
siﬁcation (mSMART) which segregates patients into three
prognostic groups: high, intermediate and standard accord-
ing to genetic alterations. High risk MM is characterized byte da Medula Ossea, Instituto Nacional de Câncer, Prac¸a da Cruz
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/)
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5, 7, 9, 11, 15, 19, and 21), t(11;14) and t(6;14). With the excep-
tion of the chromosome 13 deletion which shows prognostic
value only if detected by cytogenetics; all other alterations are
best evaluated by FISH.2
It seems that FISH will remain the standard technique to
detect alterations and subsequent stratiﬁcation of MM into dif-
ferentiated risk groups until genomic analysis becomes easy to
interpret and cheaper. A recent review from the International
Myeloma  Working Group (IMWG) pinpointed three speciﬁc
aberrations, namely the IGH/FGFR3 fusion gene, 1q21gain, and
TP53 loss, as markers to stratify high-risk MM patients at diag-
nosis and recommend their use in the routine practice.3
Two points should be emphasized regarding the genetic
changes that drive risk stratiﬁcation of patients with MM.
The ﬁrst is that the single most important genetic progno-
stic factor in MM,  irrespective of treatment, the del(17p) [TP53
mutation], is not an early event in MM pathogenesis and is
more  commonly detected during progression. The other is that
the clonal architecture of MM at diagnosis is characterized by
multiple clones and shift during progression mainly due to
therapy. This may imply that prognostic evaluations need to
be performed not only at diagnosis but also during treatment.
Finally, it is worth noting that the current genetic
classiﬁcation is based on patients treated with chemother-
apy associated or not to autologous transplantation. New
therapies based on proteasome inhibitors, immunomodula-
tors (IMiDs) and target-speciﬁc drugs are being introduced.
Whether this same set of genetic alterations will be sufﬁcient
to individualize therapy for MM  patients in the context of pro-
teasome inhibitors and IMiDs remains to be deﬁned.
Alternative  methods  for  detecting  genetic
alterations  in  multiple  myeloma  samplesaCGH is an alternative technology to test copy number varia-
tions that may gain a place in MM genetic stratiﬁcation in the
near future. The use of an oligonucleotide 8 × 60 K aCGH
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platform complemented with iFISH for t(4;14)[IGH-
FGFR3/MMSET] has recently been described for the routine
diagnostic setting of MM patients.4
While this approach is vulnerable in detecting small and
low numbers of clonal alterations at the TP53 locus when
compared to iFISH, it was more  effective in detecting cryptic
losses within the IGH region [14q32]. It was suggested that
this approach was cost neutral when compared with FISH
screening and offers the advantage of a whole genome scan.
Then again, there are suggestions that the use of gene
expression proﬁles (GEP) as a technique to detect transloca-
tions in the detection of the 17p deletion may replace iFISH
as a tool for risk stratiﬁcation in MM. Finally, next generation
sequencing, if included in the MM evaluation, may reveal mod-
iﬁcations in important actionable targets such as KRAS, NRAS,
BRAF, FGFR3, CCND1, IDH1, and IDH2.
Nevertheless, until high-resolution techniques are ready to
enter the clinical practice, FISH will probably continue to be
the best tool to establish a prognosis for MM patients.
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